Abstract Library

#4251 Upfront Oxaliplatin–Fluoropyrimidine chemotherapy and Somatostatin Analogues (SSA) in advanced well-differentiated G2/G3 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are frequently diagnosed at advanced stage. For well-differentiated somatostatin receptor-positive (SSTR +) NETs, somatostatin analogues (SSAs) are the preferred first-line therapy. However, in patients (pts) with G2/G3 and a high tumor burden, SSA alone might not be enough.

Conference:

Presenting Author:

Authors: Maratta M, Sparagna I, d'Agostino F, Occhipinti D, Raia S,

Keywords: gastroenteropancreatic NET, neuroendocrine tumor, chemotherapy, conversion surgery, neoadjuvant treatment,

#3880 Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium – Comparison of clinico-pathological and survival outcomes

Introduction: The role of peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment in patients with is still controversial, although recent experiences showed encouraging results in terms of oncological outcomes.

Conference:

Presenting Author: Genova L

Authors: Genova L, Andreasi V, Partelli S, Muffatti F, Battistella A,

Keywords: peptide receptor radionuclide therapy, prrt, neoadjuvant, surgery, yttrium, lutetium,

#3851 68Ga-DOTATOC PET radiomics as a novel preoperative predictive tool for PanNETs aggressiveness

Introduction: The knowledge of Pancreatic Neuroendocrine Tumors (PanNETs) features of aggressiveness before surgery is fundamental for an appropriate treatment planning.

Conference:

Presenting Author:

Authors: Mapelli P, Bezzi C, Ghezzo S, Muffatti F, Andreasi V,

Keywords: 68Ga-DOTATOC, NET, PET, radiomics,

#3406 Neoadjuvant treatment in locally advanced pancreatic neuroendocrine tumor G3

Introduction: Bordeline or locally advanced pancreatic neuroendocrine tumors are potentially resectable in selected cases. The role of neoadjuvant chemotherapy has not been established, and there are published only few small studies dealing with this issue.

Conference:

Presenting Author: Pindura M

Authors: Pindura M, Kyčina R, Palkoci B, Nosakova L, Uhrík P,

Keywords: pancreatic neuroendocrine tumor, neoadjuvant treatment, surgery, locally advanced neuroendocrine pancreatic tumor,

#3328 Role of neoadjuvant PRRT in resectable/borderline resectable PanNETs: Clinical, pathological and genomic features

Introduction: The role of preoperative therapies to obtain cytoreduction, especially PRRT, is unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Fumagalli A

Authors: Fumagalli A, Pellicciari M, Reni A, Borghesani M, Zaninotto E,

Keywords: net, prrt, neuroendocrine tumor, pancreas, genomic, neoadjuvant treatment,